CN Mobile Logo


Anna Azvolinsky, PhD

Anna Azvolinsky, PhD

Freelance science writer and frequent Cancer Network and OncoTherapy Network contributor.

Follow Her on Twitter

Posts by Author

A program implemented in New York City successfully increased colorectal cancer screening rates and diminished racial and ethnic disparities in screening.

The FDA has approved the anti–PD-1 immunotherapy nivolumab (Opdivo) for the treatment of metastatic renal cell carcinoma.

Researchers have developed a blood-based assay that detects ESR1 mutations in circulating tumor DNA and could predict treatment failure in breast cancer patients.

Compared to the general population, the rate of suicide is three times more frequent among head and neck cancer patients, according to a retrospective study.

The targeted therapy, nivolumab (Opdivo, Bristol Myers Squibb), improved median overall survival by 5.4 months among patients with previously treated renal cell carcinoma (RCC) compared to standard of care everolimus (Afinitor).

A review by the European Medicines Agency shows that the HPV vaccine does not cause complex regional pain syndrome and postural orthostatic tachycardia syndrome.

A new study suggests that certain mutagens formed during the cooking of meat are linked to a risk of renal cell carcinoma (RCC).

Preoperative bevacizumab may predominantly benefit breast cancer patients with a high baseline microvessel density, according to a new study.

Researchers have developed a blood test that can identify mutations in the androgen receptor gene that drive resistance to abiraterone. The test could identify prostate cancer patients who will not respond to the treatment.

For men with prostate cancer undergoing radiation therapy, consumption of men’s health supplements are unlikely to prevent adverse events, metastasis, or cancer-related death.


By clicking Accept, you agree to become a member of the UBM Medica Community.